-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OlqsMa1+LKef6BbtDo5OIa99P6YmryurUz7fR1JN6O/Yka2q05N4oGGjybQUIqv1 ijI4kPt0XAyjixaHBxdeKg== 0000914317-99-000333.txt : 19990518 0000914317-99-000333.hdr.sgml : 19990518 ACCESSION NUMBER: 0000914317-99-000333 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990517 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MERIDIAN MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000095676 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 520898764 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: SC 13D SEC ACT: SEC FILE NUMBER: 005-35771 FILM NUMBER: 99628436 BUSINESS ADDRESS: STREET 1: 10240 OLD COLUMBIA RD STREET 2: STE 100 CITY: COLUMBIA STATE: MD ZIP: 21046 BUSINESS PHONE: 4103096830 MAIL ADDRESS: STREET 1: 10240 OLD COLUMBIA ROAD CITY: COLUMBIA STATE: DE ZIP: 21046- FORMER COMPANY: FORMER CONFORMED NAME: SURVIVAL TECHNOLOGY INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: COMMONWEALTH BIOVENTURES INC CENTRAL INDEX KEY: 0000900884 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 042984136 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 4 MILK ST CITY: PORTLAND STATE: ME ZIP: 04101 BUSINESS PHONE: 2077800904 MAIL ADDRESS: STREET 1: 4 MILK ST CITY: PORTLAND STATE: ME ZIP: 04101 SC 13D 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Meridian Medical Technologies, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock COMMON STOCK, $.010 par value - -------------------------------------------------------------------------------- (Title of Class of Securities) 589658103 - -------------------------------------------------------------------------------- (CUSIP Number) Robert G. Foster, 4 Milk Street, Portland, ME 04101 - -------------------------------------------------------------------------------- (Name, Address, Telephone Number of Persons Authorized to Receive Notices and Communications) April 5, 1999 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. Page 1 of Pages 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON Commonwealth Bioventures, Inc. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS [ ] REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts - -------------------------------------------------------------------------------- NUMBER OF SHARES 7 SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 0 ------------------------------------------------ 8 SHARED VOTING POWER 439,947 ------------------------------------------------ 9 SOLE DISPOSITIVE POWER 0 ------------------------------------------------ 10 SHARED DISPOSITIVE POWER 439,947 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 439,947* - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.69% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN* Beneficial ownership expressly disclaimed. - -------------------------------------------------------------------------------- ITEM 1. SECURITY AND ISSUER. The class of securities to which this Schedule relates is Common Stock, $.10 par value of Meridian Medical Technologies, Inc., a Delaware corporation (the "Issuer"). The address of the principal executive office of the Issuer is: Meridian Medical Technologies, Inc. 10240 Old Columbia Road Columbia, Maryland 21046 ITEM 2. IDENTITY AND BACKGROUND. The reporting person's name is Commonwealth BioVentures, Inc., a Massachusetts corporation with a principal business and office address of 4 Milk Street, Portland, ME 04101. The reporting person's principal business is that of the general partner of BioVenture Partners Limited Partnership ("BPLP"), which is the manager of two venture capital funds, Commonwealth BioVentures IV Limited Partnership ("Fund IV") and Commonwealth BioVentures V Limited Partnership ("Fund V"). During the last five years, the reporting person has not been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors). During the last five years, the reporting person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding has been or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. This item is not applicable to the reporting person. ITEM 4. PURPOSE OF TRANSACTION. This item is not applicable to the reporting person. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) The number of securities of the Issuer which the reporting person may be deemed to beneficially own is 439,947. Of those, 162,756 represent securities which the reporting person may be deemed to have the right to acquire within 60 days. This aggregate represents approximately 14.69% of the Issuer's outstanding class of such securities. The reporting person expressly disclaims beneficial ownership of all securities reported in this Schedule. (b) The reporting person does not have the sole power to vote and the sole power to dispose of any of the shares of the Issuer's securities. By virtue of its position as general partner of BPLP, the reporting person may be deemed to share the power to vote and share the power to dispose of the following Common Stock of the Issuer with BPLP and the entities so indicated: (i) 120,382 shares with Fund IV and (ii) 319,565 with Fund V. However, the reporting person expressly disclaims beneficial ownership of these shares. The business address of BPLP, Fund IV and V is 4 Milk Street, Portland, ME 04101. Fund IV and V are venture capital funds and BPLP is the general partner of Fund IV and V. Within the last five years, neither BPLP, Fund IV or V have been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or have been a party to a civil proceeding of a judicial administrative body of competent jurisdiction and as a result of such proceeding have been or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (c) Fund IV sold 20,000 shares of the Issuer's Common Stock in a public sale between April 5, 1999 and April 19, 1999. Specifically, Fund IV sold 100 shares on April 5, 1999 at $5.25 per share; 3,700 shares on April 6, 1999 at $5.00 per share; 3,000 shares on April 9, 1999 at $4.50 per share; 8,200 shares on April 15, 1999 at $4.0076 per share; 2,000 shares on April 16, 1999 at $4.00 per share; and 3,000 shares on April 19, 1999 at $4.00 per share. Fund V sold 20,000 shares of the Issuer's Common Stock in a public sale between April 12, 1999 and April 19, 1999. Specifically, Fund V sold 3,300 shares on April 12, 1999 at $4.125 per share; 10,000 shares on April 14, 1999 at $4.00 per share; and 6,700 shares on April 19, 1999 at $4.00 per share. (d) Not applicable. (e) Not applicable. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. This item is not applicable to the reporting person. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. This item is not applicable to the reporting person. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. COMMONWEALTH BIOVENTURES, INC. 5/14/99 By: /s/ Robert G. Foster --------------------- ------------------------- Date Robert G. Foster, President -----END PRIVACY-ENHANCED MESSAGE-----